Cost of measles containment in an ambulatory pediatric clinic

Pediatr Infect Dis J. 2015 Jun;34(6):589-93. doi: 10.1097/INF.0000000000000682.

Abstract

Background: Measles is highly infectious; prompt containment of illnesses is necessary to prevent spread. In August 2013, a 13-year-old male with measles exposed patients and employees in a pediatric clinic. We studied containment costs to identify avoidable costs.

Methods: Measles exposure was defined as in-person contact with or presence in the same room <2 hours after the measles patient. Costs were calculated retrospectively using published costs of measles-mumps-rubella vaccine, cost-to-charge ratios for inpatient care in urban Washington State and local emergency department charges for post-exposure immunoglobulin (IG). Personnel costs were calculated by multiplying hourly wages by time for employees who worked on the response; overhead was excluded.

Results: Fifty-two patients, 60 caretakers and 10 employees were exposed. Personnel time cost $1961. Exposed patients had a mean age of 9.6 years (range: 2 months-19 years); 34 (65%) were fully vaccinated, and 18 (35%) were <12 months of age and too young to be vaccinated. Five patients (10%) were <6 months of age and required IG; 13 infants (25%) 6-11 months of age required measles-mumps-rubella vaccination. Caretakers followed up with their physicians for evidence of immunity. One employee had documented evidence of immunity; 9 required measles antibody testing or vaccination. Management of exposed persons cost $3694; overall clinic costs were $5655.

Conclusion: Responding to 1 measles case cost the pediatric clinic more than $5000, despite isolating the patient promptly after examination. Documentation of employee immunity, vaccination of eligible patients and strict infection control precautions might reduce ambulatory costs associated with measles containment.

MeSH terms

  • Adolescent
  • Ambulatory Care Facilities*
  • Child
  • Child, Preschool
  • Female
  • Health Care Costs*
  • Humans
  • Immunoglobulins, Intravenous / administration & dosage
  • Immunoglobulins, Intravenous / economics
  • Infant
  • Infection Control / economics*
  • Infection Control / methods*
  • Male
  • Measles / epidemiology*
  • Measles / prevention & control*
  • Measles Vaccine / administration & dosage
  • Measles Vaccine / economics
  • Post-Exposure Prophylaxis / economics
  • Post-Exposure Prophylaxis / methods
  • Retrospective Studies
  • Washington
  • Young Adult

Substances

  • Immunoglobulins, Intravenous
  • Measles Vaccine